WO2001009611A3 - An vivo identification of specific binding molecules for cancer detection - Google Patents

An vivo identification of specific binding molecules for cancer detection Download PDF

Info

Publication number
WO2001009611A3
WO2001009611A3 PCT/US2000/020273 US0020273W WO0109611A3 WO 2001009611 A3 WO2001009611 A3 WO 2001009611A3 US 0020273 W US0020273 W US 0020273W WO 0109611 A3 WO0109611 A3 WO 0109611A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
subject
specific
specific binding
methods
Prior art date
Application number
PCT/US2000/020273
Other languages
French (fr)
Other versions
WO2001009611A2 (en
Inventor
David N Krag
Lyn Oligino
Original Assignee
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont filed Critical Univ Vermont
Priority to AU66086/00A priority Critical patent/AU6608600A/en
Publication of WO2001009611A2 publication Critical patent/WO2001009611A2/en
Publication of WO2001009611A3 publication Critical patent/WO2001009611A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Abstract

Methods of identifying a subject-specific, tissue-specific binding molecule in a human subject are provided. The method involves injecting a library of molecules into a human and identifying molecules which bind to a specific tissue. The binding molecule can be used to direct drugs to the specific tissue of the human to treat various diseases such as cancer. The method can also be used to direct an immunomodulatory molecule to a tissue to stimulate the production of a local immune response at the tissue. The methods are particularly advantageous in developing individualized therapies. The methods can also be used to detect cancer cells in a subject after treatment for cancer and preferably from a subject who has undergone surgery.
PCT/US2000/020273 1999-07-29 2000-07-26 An vivo identification of specific binding molecules for cancer detection WO2001009611A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66086/00A AU6608600A (en) 1999-07-29 2000-07-26 In vivo methods for the identification of target specific binding molecules in a human and their use in cancer detection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36422899A 1999-07-29 1999-07-29
US09/364,228 1999-07-29

Publications (2)

Publication Number Publication Date
WO2001009611A2 WO2001009611A2 (en) 2001-02-08
WO2001009611A3 true WO2001009611A3 (en) 2001-11-22

Family

ID=23433598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020273 WO2001009611A2 (en) 1999-07-29 2000-07-26 An vivo identification of specific binding molecules for cancer detection

Country Status (2)

Country Link
AU (1) AU6608600A (en)
WO (1) WO2001009611A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049140B1 (en) 1999-04-29 2006-05-23 Vanderbilt University X-ray guided drug delivery
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
ATE434184T1 (en) 2001-11-20 2009-07-15 Univ Duke INTERFACE BIOMATERIALS
DE10224338A1 (en) * 2002-05-29 2003-12-24 Gerald-F Gerlach Means and methods for the enrichment and detection of microorganisms
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
WO2016014939A1 (en) 2014-07-24 2016-01-28 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
WO2018148595A1 (en) 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007214A1 (en) * 1978-07-07 1980-01-23 Samuel Dr. Bogoch Product for detecting the presence of cancerous or malignant tumor cells
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007214A1 (en) * 1978-07-07 1980-01-23 Samuel Dr. Bogoch Product for detecting the presence of cancerous or malignant tumor cells
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 *
BARRY MICHAEL A ET AL: "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries.", NATURE MEDICINE, vol. 2, no. 3, 1996, pages 299 - 305, XP002156129, ISSN: 1078-8956 *
PASQUALINI R & RUOSLAHTI E: "Organ targeting in vivo using display peptide libraries", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 380, no. 6572, 28 March 1996 (1996-03-28), pages 364 - 366, XP002128874, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
AU6608600A (en) 2001-02-19
WO2001009611A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2001009611A3 (en) An vivo identification of specific binding molecules for cancer detection
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003069553A3 (en) Method of image analysis
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003040725A3 (en) Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP